214 results about "Prostaglandin" patented technology

The invention belongs to the technical field of microorganisms, and provides streptococcus salivarius subsp. Thermophilus HX-ST36, and the preservation number of the streptococcus salivarius subsp. Thermophilus HX-ST36 is CGMCC NO.32955. The streptococcus salivarius subsp. Thermophilus provided by the invention can be used for fermenting astragalus membranaceus-angelica sinensis. In a cold coagulation and blood stasis type primary dysmenorrheal model mouse, a fermentation product can remarkably inhibit the writhing reaction, and the effects of relieving dysmenorrheal and enriching blood can be achieved by reducing the levels of prostaglandin PGF2 and vasopressin ADH in uterine tissue and increasing the content of hemoglobin (HGB). The dampness clearing effect of the fermentation product is verified by improving the heavy physical sign of moisture through crowd experiments. The invention also provides a preparation method of the probiotic preparation and the probiotic fermentation product. The preparation methods of the probiotic preparation and the probiotic fermentation product are simple, and large-scale production can be realized.

The invention relates to a preparation method of a lophatherum gracile extract as well as a product and application of the lophatherum gracile extract. The preparation method comprises the following steps: mixing a lophatherum gracile raw material with an ethanol water solution, then carrying out microwave-ultrasonic combined treatment, then carrying out reflux extraction, carrying out vacuum concentration on an extracting solution, and carrying out purification and elution on a concentrated solution by adopting macroporous resin to obtain the lophatherum gracile extract. And carrying out flocculation treatment on the eluent, and then drying to obtain the lophatherum gracile extract. The extract prepared by the preparation method is clear in effective components, has excellent DPPH free radical scavenging capacity and prostaglandin and capsaicin receptor inhibition capacity, is free of pesticide residues, can be used as an active component of skin care products and medical auxiliary supplies, and has the effects of resisting oxidation, resisting inflammation and relieving.

Compounds and methods of modulating 15-PGDH activity, modulating tissue prostaglandin levels, treating disease, diseases disorders, or conditions in which it is desired to modulate 15-PGDH activity and / or prostaglandin levels include 15-PGDH inhibitors described herein.

The present invention provides a compound having a hematopoietic prostaglandin D synthase (H-PGDS) inhibitory activity and being useful for preventing or treating a disease involving the enzyme, and a pharmaceutical composition comprising the compound. Specifically, the present invention provides a compound represented by Formula (I) below or a pharmaceutically acceptable salt thereof:[wherein —X═ represents —CH═ or the like; ═Y— represents ═CH— or the like; R1 and R2 each independently represent a hydrogen atom or the like; R3 represents a hydrogen atom or the like; and Z is a group represented by Formula (II):(wherein the wavy line represents the point of attachment to the nitrogen atom; ring Z1 represents a C6-10 aryl group or the like; m represents 0, 1, or 2; and R4 represents a halogen atom or the like.) or Formula (III):(wherein the wavy line represents the point of attachment to the nitrogen atom; ring Z2 represents a C6-10 aryl group or the like; L represents a single bond or the like; ring Z3 represents a C6-10 aryl group or the like; n represents 0, 1, or 2; and R5 represents a halogen atom or the like.]

The invention belongs to the technical field of medicines, and particularly relates to application of prostaglandin E2 in preparation of a medicine for treating retina injury caused by blue light exposure. The prostaglandin E2 medicine or the medicine composition is used for preventing or treating retina injury caused by blue light exposure, the medicine or the medicine composition has the functions of relieving shortening of a retina photoreceptor cell layer and relieving decline of retina electrophysiology a waves and b waves, and then pathological changes related to retina diseases can be improved.

The present invention relates to a method for in vitro sorting of target cells for cell therapy, belonging to the technical field of cell therapy. The present invention utilizes a washing solution containing EGTA, EDTA, α-casein, and prostaglandins to achieve a sorting method with high viable cell recovery efficiency, thereby enabling better cell therapy.

The invention belongs to the technical field of biology, and particularly relates to a composition for tumor targeted therapy, hydrogel and a preparation method and application thereof. The tumor targeted therapy composition provided by the invention comprises the aging tumor cells and the celecoxib, the immune activation function of the aging tumor cells is that STCs can effectively activate the maturation of dendritic cells and the immune function of T cells and NK cells, SASP of the STCs is regulated through the celecoxib, especially generation of prostaglandin E2 is inhibited, and the tumor targeted therapy effect is improved. And the combined use further enhances the anti-tumor immune effect.

The disclosure relates to the medical use of inhibitors of expression or function of the hematopoietic prostaglandin synthase (HPGDS) in the treatment of cancer in general or more in particular in the treatment of cancer in which HPGDS is predominantly expressed by tumor-associated macrophages in the tumor micro-environment. Inhibition of HPGDS as enhancer of immune checkpoint inhibitor therapy is also disclosed, as are (companion) diagnostic methods. The disclosure further relates to isolated macrophages in which HPGDS expression or function is inhibited, such as for medical use.

The present invention describes a composition comprising an effective amount of a combination of two or more components selected from acacetin, ACT1 peptide, α-lipoic acid, alprostadil, anisomycin, apigenin, ascorbic acid, astragalus, berberine, β-lapachone, β-hydroxy-β-methylbutyrate, bacopa monnieri, catechins, catechols, chamomile, chrysin, coumestrol, curcumin, dinitrophenol, dinoprost, ellagic acid, (-)-epigallocatechin gallate, green tea extract, fisetin, genistein, ginsenoside RE, glabridin, 18-α-glycyrrhetinic acid, 18-β-glycyrrhetinic acid, glycyrrhizin, hydroquinone, isoquercetin (EMIQ), shan Phosphate, black bean anthocyanins, leucine, lithium, luteolin, luteolin, luteolin, melatonin, menadione, 1‑methylnicotinamide (MNA), methyl salicylate, myricetin, nicotinamide adenine dinucleotide, nicotinic acid (vitamin B3), nicotinamide (NAM), nicotinamide mononucleotide (NMN), nicotinamide riboside (NR), nicotinic acid adenine dinucleotide (NaAD), nicotinic acid mononucleotide (NaMN), parsley, phenylephrine, pokeweed mitogen, 15‑Δ prostaglandin J2, puromycin, quercetin, quinolinic acid, retinoic acid, trichostatin A, troxerutin, rutin, tryptophan, vitamin D3, withaferin A, wortmannin, and zinc (including its salts).

The invention discloses a lung cancer organoid culture medium, a culture medium system and a culture method thereof, the culture medium system comprises an initial culture medium, an amplification culture medium and a differential culture medium, and the initial culture medium comprises an Advanced DMEM / F12 basal culture medium, Glutamax, nicotinamide, R-spondin-1, rhNoggin, FGF-7, FGF-10, B27, Y-27632, A83-01, SB202190 and prostaglandin E2. Hydrocortisone and Forskolin are added into the amplification culture medium; hydrocortisone and dexamethasone are added into the differential culture medium, and the culture medium system is adopted for lung cancer organoid culture. Cells obtained from lung cancer tissues are subjected to primary lung cancer organoid culture in the initial culture medium; then, transferring the obtained lung cancer organoid cells into an amplification culture medium for amplification culture; and then, transferring the lung cancer cells into a differential culture medium for differential culture to obtain the lung cancer organoid.

Provided are intermittent dosing methods for treating a condition associated with increased 15-hydroxyprostaglandin dehydrogenase (15-PGDH) activity or expression levels in a subject with a 15-PGDH inhibitor to reduce toxicity. Further, provided herein are methods of treating a condition associated with increased 15-hydroxyprostaglandin dehydrogenase (15-PGDH) activity or expression levels in a subject by administering a 15-PGDH inhibitor when the plasma concentration of the 15-PGDH inhibitor in the subject falls below the EC50 of the 15-PGDH inhibitor, while maintaining therapeutic efficacy of the 15-PGDH inhibitor.

The invention discloses a culture medium and a culture method of appendix mucinous tumor organoid. The culture medium of the appendix mucinous tumor organoid is prepared by adding the following components with final concentration into a basic culture medium: 2-8nM of NRG1 and 1-2mu g / ml of R-Spondin1, 90 to 110 [mu] g / ml of Noggin; 70 to 80 [mu] g / ml of Wnt-3a; eGF with a concentration of 45 to 55 ng / ml; the concentration of the FGF-10 is 90 to 110 ng / ml; 1X B to 27TM; 4 to 6 mM of nicotinamide; 4 to 6 nM of prostaglandin E2; 9 [mu] g / ml to 11 [mu] g / ml of Transferrin human; 4-6 [mu] g / ml of insulin; 4 to 6 nM of gastrin I; 9 to 11 [mu] M of Y27632; 1 to 2 [mu] M of A83-01; 4 to 6 [mu] M of SB202190; and 2 to 3 [mu] M of CHIR999021. The culture medium is high in induction rate.

The invention provides a plant lactobacillus IOB602 and an application of a metagen of the plant lactobacillus IOB602 in relieving arthritis swelling, and belongs to the technical field of microbial fermentation. The phytobacterium plantarum IOB602 and the metagen can be used for inhibiting the foot swelling degree of the mouse; the content of inflammatory factors TNF-alpha and IL-1beta in a mouse body is inhibited, and inflammatory response is relieved; the content of NO in toes of mice is reduced, and the activity of SOD is improved; the content of prostaglandin E2 (PGE2) in toes of mice is inhibited to relieve foot swelling inflammation pain; edema and hyperplasia degree of toes of the mouse are relieved, infiltration of inflammatory cells is reduced, and then arthritis swelling is relieved.

The invention relates to the technical field of equipment control, and discloses a control method of a wave conduction health care instrument capable of outputting different waveforms based on symptoms, and the method comprises the steps: transmitting a 1-10MHz multi-frequency detection wave to a target treatment area, calculating tissue impedance distribution through a reflected wave, and obtaining a focus boundary coordinate based on an impedance difference threshold; on the basis of the impedance-frequency response curve, an inverse phase compensation waveform is generated through a time reversal algorithm, the inverse phase compensation waveform comprises a phase delay component in negative correlation with the impedance curve, and tissue scattering distortion is counteracted; synchronously starting the electrical stimulation module and the ultrasonic module; the focus coordinates are repeatedly updated every 30 seconds, and the electrical stimulation focusing position is adjusted; the concentration of lactic acid and the concentration of prostaglandin E2 in tissue fluid are detected in real time through a microfluidic sensor, and correction is triggered when any concentration exceeds the limit, specifically, lactic acid ultralimit switching electrical stimulation is 50-100 Hz damped oscillatory waves (larger than or equal to 5 minutes), prostaglandin E2 ultralimit switching ultrasound is in a pulse mode, and the electrical stimulation amplitude is increased. The treatment effect of the waveform treatment equipment can be improved.

The invention relates to a composition comprising from 0.1 to 8.0 mg / g of composition of at least one xanthophyll, from 1.0 to 45.0 mg / g of composition of at least one omega-3 fatty acid, from 0.02 to 0.8 mg / g of composition of at least one sterol, from 0.05 to 1.5 μg / g of composition of at least one phycoprostane and from 700 to 990 mg / g of at least one vegetable oil. The composition is used to provide a soothing effect on the skin and / or to maintain homeostasis.

Kit (1) containing an oil-in-water emulsion (2) and a stabilizing container (3); wherein the oil-in-water emulsion (2) is contained in the stabilizing container (3); wherein the stabilizing container (3) is an aluminium container; and the oil-in-water emulsion (2) comprises: at least one prostaglandin at least one oil selected from triglyceride oils, at least one non-ionic surfactant selected from polysorbates and sorbitan esters, at least one cationic agent selected from quaternary ammonium compounds, and Water.

The invention relates to the technical field of analysis and detection, and discloses a method for detecting cigarette smoke exposure biomarkers based on nanofiber solid-phase extraction, which comprises the following steps of: treating biological samples such as liver, lung, blood and urine samples by using a polystyrene / polypyrrole nanofiber material as a solid-phase extraction material; and simultaneously detecting a plurality of cigarette smoke biomarkers and an oxidative stress marker 8-isoprostaglandin in different biological samples of the rat after smoke exposure by using a liquid chromatography-mass spectrometer. According to the method, the influence of toxic and harmful substances in cigarette smoke on the health of organisms is reflected by detecting smoke exposure biomarkers and oxidative stress markers in biological samples, and evaluation of the safety performance of tobacco products is facilitated. According to the method, the limitation of small target object coverage of the existing smoke exposure biomarker detection method is solved, and the problems of large use amount of an organic solvent and tedious and time-consuming pretreatment in the existing sample pretreatment are also solved.

Provided are: a culture medium which is for producing an organoid and which comprises a prostaglandin, hepatocyte growth factor (HGF), an interleukin (IL)-6 family protein, and an epidermal growth factor (EGF) family protein; a kit for cultivating an organoid; a method for producing an organoid; and an organoid.

The invention discloses an anti-drunkenness composition and application thereof. The invention provides an application of a composition in preparation of an anti-drunkenness product, the composition contains edible plasma powder, xylitol, fructo-oligosaccharide, microcrystalline cellulose, mogroside and magnesium stearate, and the edible plasma powder contains immune globulin IgG. The TZK provided by the invention has obvious regulation and improvement effects on sleep behaviors, serum indexes and gastrointestinal injury after acute drinking. The oxidative stress state after long-term large-dose chronic drinking is effectively adjusted, so that the oxidative stress injury index malondialdehyde (MDA) gradually returns to the normal level; according to the present invention, the activity of the liver injury markers such as alanine transaminase (ALT) and aspartate transaminase (AST) is reduced, the liver protection effect is provided, and the gastric mucosa structure repair is promoted by increasing the gastric mucosa prostaglandin content and reducing the local MDA level;

This invention provides a method for the simultaneous and rapid detection of four oxidative stress-related biomarkers and its application. The detection method includes: (S1) pretreatment of samples using a protein precipitation extract to simultaneously extract four target compounds: 8-hydroxydeoxyguanosine, 8-isoprostaglandin F2β, 8-isoprostaglandin F2α, and acetyllysine, and preparing a test solution; the protein precipitation extract is a methanol-acetonitrile-perchloric acid mixed solution containing formic acid, wherein the volume ratio of methanol, acetonitrile, and perchloric acid is (8-10):(8-10):(0.5-1), and the volume concentration of formic acid is 0.1-0.5%; (S2) detection of the test solution and standard solution using liquid chromatography-tandem mass spectrometry, and matrix calibration using an internal standard method; plotting a standard curve with the peak area ratio of the target compound to the internal standard as the ordinate and the concentration as the abscissa; and calculating the concentration of the target compound in the test solution based on the standard curve.

Provided are intermittent administration methods for reducing toxicity in the treatment of conditions associated with increased 15-hydroxyprostaglandin dehydrogenase (15-PGDH) activity or expression levels in a subject with a 15-PGDH inhibitor. Further, provided herein are methods of treating a condition associated with increased 15-hydroxyprostaglandin dehydrogenase (15-PGDH) activity or expression level in a subject by administering a 15-PGDH inhibitor while maintaining the therapeutic effect of the 15-PGDH inhibitor when the plasma concentration of the 15-PGDH inhibitor in the subject drops below the EC50 of the 15-PGDH inhibitor.

The invention provides a special culture medium for prostate cancer organoid and a culture method thereof, and belongs to the technical field of biological medicines. The special culture medium for the prostatic cancer organoid is composed of a basic culture medium and a culture additive, and the basic culture medium does not contain exogenously added Noggin recombinant protein and R-spondin recombinant protein. The culture additive is prepared from a basic fibroblast growth factor, a keratinocyte growth factor, a fibroblast growth factor 10, insulin, a p38MAPK signal channel inhibitor, an insulin-like growth factor 1, B27, nicotinamide, N-acetylcysteine, hydrocortisone, a ROCK kinase inhibitor, retinoic acid, interleukin 6, prostaglandin E2, a eriocin and androgen. According to the special culture medium for the prostatic cancer organoid, the culture success rate is increased while the cost is reduced.

A transdermal treatment for erectile dysfunction includes an aqueous solution having a plurality of excipients and a combination of papaverine, phentolamine mesylate and prostaglandin E1.

A drug-polymer conjugate, which is a copolymer of at least one monomer of formula (I) where: X may be the same or different at each occurrence and represents a terminal functional group comprising an alkyne or an azide; Q is independently selected at each occurrence and may be present or absent and when present, represents a linking group; R is selected from the group consisting of linear or branched hydrocarbon, optionally substituted aryl and optionally substituted heteroaryl; D is a releasable bicyclic prostaglandin; L is a linker group; and at least one co-monomer of Formula III J-(Y1-A)n, J represents a linking functional group, n is 2 to 8 preferably 3 to 8; Y1 comprises a polyether of formula (ORa)m wherein Ra is independently ethylene, propylene and butylene and m is from 1 to 300 (preferably 2 to 300) and the polyether is in chain with one or more groups which are preferably selected from one or more of optionally substituted straight or branched C1 to C10 alkylene, amino, ether, ester, amide, carbonate and carbamate; A may be the same or different at each occurrence and represents a group comprising a terminal functional group comprising an alkyne or an azide functionality, wherein said terminal functional group is complementary to the terminal functional group X of formula (I) providing triazole moieties from reaction of X and A.

The present invention relates to a process for the preparation of a chiral prostaglandin enol intermediate of formula 1, comprising the steps of: separating a compound of formula 16-(R,S)-10 into its diastereomers by fractional crystallisation, reducing the 15-oxo group of the compound of formula 16-(R)-10, thereby obtaining a compound of formula 15-(R,S), 16-(R)-11, followed by removing the protecting group of the compound of formula 15-(R,S), 16-(R)-11, and isolating the compound of formula 1, and optionally, crystallizing the compound of formula 1. Optionally, the undesired isomer formed during fractional crystallization can be epimerized and further amount of the desired isomer can be recovered from the resulting mixture. The present invention also provides novel intermediates useful in the process. The invention further relates to a process for fractional crystallization of the compound of formula 16-(R,S)-10.

The invention discloses blood filtration replacement liquid as well as a preparation method and application thereof. The displacement liquid comprises low molecular weight heparin calcium, prostaglandin E1, prostacyclin, electrolyte with specific concentration, glucose and an interleukin-1 receptor antagonist. The preparation method comprises the following steps: weighing the raw materials according to the proportion, dissolving to a constant volume, removing pyrogen and heat, and carrying out aseptic packaging. During clinical application, replacement liquid and blood are filtered according to the replacement rate of 1: 1-2: 1 according to the condition of a patient, 4-6 hours each time and 2-3 times each week, and related indexes are monitored. Animal tests show that the replacement liquid has good safety under the effective dosage, and has potential influence on part of organs under the high dosage. A stability test shows that the compound can be stably stored under a certain condition. The invention provides the replacement liquid which can achieve anticoagulation and blood vessel protection, maintain electrolyte balance and relieve inflammatory response, is expected to improve the prognosis of hemodialysis patients, and has important clinical significance and wide application prospects.

The present invention relates to compounds of formula (I) and pharmaceutical compositions comprising these compounds. The compounds provided herein can be used as prostaglandin E2 (PGE2) EP4 receptor antagonists, which makes them very useful for therapy, particularly for the treatment or prevention of cancer, neovascular eye disease, inflammatory pain or inflammatory diseases such as multiple sclerosis, rheumatoid arthritis or endometriosis. #imgabs0#

The present invention provides a culture medium for primary ovarian cancer cells, an in vitro culture method, and applications thereof. The culture medium comprises an MST1 / 2 kinase inhibitor; at least one Rho protein kinase inhibitor selected from Y27632, fasudil, and H-1152; an insulin-transferrin-selenium supplement; insulin; prostaglandin E2; epidermal growth factor; gastrin; insulin-like growth factor-1; cholera toxin; amphiregulin; N2; and B27. Compared to existing culture methods, in vitro culture using the culture medium of the present invention has higher expansion efficiency. Culturing primary ovarian cancer cells using this culture medium can maintain the morphological structure and pathological characteristics of the primary tissue, thereby improving the success rate and survival rate of primary ovarian cancer cell culture.

The present disclosure relates to genetically modified host cells producing prostaglandins, to genetic constructs for expression of such mutants; to cultures of the genetically modified host cells and its use to produce the said products; to fermentation liquids comprising the said products resulting from such production; to compositions comprising the fermentation liquid; to pharmaceutical preparations made from such compositions and to the uses of such compositions and preparations.